| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5ddced4c203e56346f054e364b141ba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-64 |
| filingDate |
1995-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97cf22aa9f455d78fca62aba26f9b565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29e447f57cd192a4b1a3c0d1085e7dfb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddfd7776022fd3e9b9516f4031f4a8fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ae2c37a62ccae0989a0439fbe1f6a2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17596fe390a87023acea81728471674a |
| publicationDate |
2002-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6395873-B1 |
| titleOfInvention |
Method and composition for treating thrombosis |
| abstract |
The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic. moiety an adjacent positively charged moiety. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03066663-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003216322-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03066663-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7094868-B2 |
| priorityDate |
1990-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |